| Join CMS for a Stakeholder Call on the Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease |
On April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) released anational policy for coverage of aducanumab (brand name Aduhelm) and any futuremonoclonal antibodies directed against amyloid approved by the FDA with an indicationfor use in treating Alzheimers disease.From the onset, CMS ran a transparent,evidence-based process that incorporated more than 10,000 stakeholder commentsand more than 250 peer-reviewed documents into the determination. As a part of CMS continued commitment to engage stakeholders on an ongoing basis,CMS will hold a national stakeholder call on May 11, 2022 to review the recent finalizedcoverage decision on monoclonal antibodies directed against amyloid for the treatmentof Alzheimers Disease. CMS will review the overall coverage process, the finalizeddecision, and address questions as time allows. When: Wednesday, May 11, 2022, 11:00 AM ET Who should attend: This stakeholder call is intended for anyone in the healthcareindustry, but specifically for healthcare issuers, providers of healthcare, andhealthcare advocates. RSVP: https://cms.zoomgov.com/webinar/register/WN_WPnryrzfS_eQnwp6Fnndag After registering, you will receive a confirmation email containing informationabout joining the webinar. This meeting is closed to press. Additional Resources: For the complete press release visit: https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment For a fact sheet on Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimers disease, visit: https://www.cms.gov/newsroom/fact-sheets/medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment-alzheimers-disease. To read the final NCD CED decision memorandum, visit: https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305 | 